EU MDR clinical evaluation Article 61 and Annex XIV overview

Article 61 ties clinical evaluation directly to MDR Annex I. The evaluation must use sufficient clinical evidence to confirm conformity with relevant general safety and performance requirements, assess undesirable side-effects, and support the acceptability of the benefit-risk ratio under normal intended use.

Annex XIV turns that obligation into a method: plan the evaluation, identify which GSPRs need clinical data, search for available clinical data and evidence gaps, appraise the data, generate additional data when needed, and analyse the evidence into conclusions on safety, clinical performance, and clinical benefits.

MDR clinical data can come from clinical investigations of the device, clinical investigations or other studies reported in scientific literature for an equivalent device, peer-reviewed literature on clinical experience with the device or an equivalent device, and clinically relevant PMS information including PMCF.

Equivalence is a constrained route, not a shortcut. Annex XIV requires technical, biological, and clinical characteristics to be considered, and MDCG 2020-5 stresses that differences must be identified, scientifically justified, and shown not to create clinically significant differences in safety or clinical performance.

Article 61 requires the clinical evaluation, its results, and the clinical evidence derived from it to be documented in a clinical evaluation report. Except for custom-made devices, that report is part of the technical documentation for the device.

A useful CER does more than cite papers. It should connect the clinical evaluation plan, literature search and appraisal, investigations, equivalence rationale if used, PMS and PMCF outputs, state of the art, IFU and claims, risk management, GSPR support, limitations, and benefit-risk conclusion.

PMCF is part of the clinical evaluation lifecycle. Annex XIV describes PMCF as the continuous process that updates the clinical evaluation, and the PMCF plan must be addressed in the manufacturer's PMS plan.

PMCF should proactively collect and evaluate clinical data from the use of the CE-marked device within its intended purpose. The results feed the PMCF evaluation report, the CER, technical documentation, risk management, and benefit-risk reassessment.

Where a notified body assesses the device, clinical evaluation is a core review area. Annex VII and conformity assessment annexes require notified bodies to review clinical evidence, challenge equivalence where claimed, verify GSPR conclusions, consider risk management, IFU, user training, PMS, PMCF adequacy, and decide whether milestones are needed for post-certification clinical evidence updates.

For certain class III and class IIb devices, additional clinical evaluation consultation procedure requirements may apply. The notified body's clinical evaluation assessment report is used to document conclusions on the manufacturer's clinical evidence, benefit-risk determination, consistency with intended purpose and medical indications, and PMCF plan.